Anhydrous Caffeine, Paracetamol Dc, Paracetamol Ph. Eur.

• A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting
  2022-502654-14-00 Phase II 4 countries Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 Phase III 9 countries UCB Biopharma
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended
  2023-506368-14-00 Phase III 13 countries UCB Biopharma
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
• A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Ended
  2023-505169-10-00 Phase II 1 country Kite Pharma Inc.
• Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple … Ended
  2022-500339-35-01 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended
  2023-503348-15-00 Phase I (FiH) 5 countries Genmab A/S

Showing 1–7 of 7 trials